INTRODUCTION: The identification of key pathways dysregulated in non-small cell lung cancer (NSCLC) is an important step toward understanding lung pathogenesis and developing new therapeutic approaches. METHODS: Toward this goal, reverse-phase protein lysate arrays (RPPA) were used to compare signaling pathways between NSCLC tumors and paired normal lung tissue from 46 patients and assess their association with clinical outcome. RESULTS: After RPPA quantification of 63 proteins and phosphoproteins, tissue pairs were randomized to a training set (n = 25 pairs) and test set (n = 21 pairs). In the training set, 15 protein markers were differentially expressed between tumors and normal lung (p ≤ 0.01), including markers in the PI3K/AKT and p38 MAPK signaling pathways (e.g., p70S6K, S6, p38, and phospho-p38), as well as caveolin-1 and β-catenin. A four-protein signature (p70S6K, cyclin B1, pSrc(Y527), and caveolin-1) independent of histology classified specimens as tumor versus normal with a predicted accuracy of 83%, sensitivity of 67%, and specificity of 100%. The signature was validated in the test set, correctly classifying all normal tissues and 14 of 21 tumor tissues. RPPA results were confirmed by immunohistochemistry for caveolin-1 and p70S6K. In tumors from patients with resected NSCLC, expression of proteins in the energy-sensing AMPK pathway (pLKB1, AMPK, p-Acetyl-CoA, pTSC2), adhesion, EGFR, and Rb signaling pathways was inversely associated with NSCLC recurrence. CONCLUSIONS: These data provide evidence for dysregulation of several pathways including those involving energy sensing and adhesion that are potentially associated with NSCLC pathogenesis and disease recurrence.
INTRODUCTION: The identification of key pathways dysregulated in non-small cell lung cancer (NSCLC) is an important step toward understanding lung pathogenesis and developing new therapeutic approaches. METHODS: Toward this goal, reverse-phase protein lysate arrays (RPPA) were used to compare signaling pathways between NSCLC tumors and paired normal lung tissue from 46 patients and assess their association with clinical outcome. RESULTS: After RPPA quantification of 63 proteins and phosphoproteins, tissue pairs were randomized to a training set (n = 25 pairs) and test set (n = 21 pairs). In the training set, 15 protein markers were differentially expressed between tumors and normal lung (p ≤ 0.01), including markers in the PI3K/AKT and p38 MAPK signaling pathways (e.g., p70S6K, S6, p38, and phospho-p38), as well as caveolin-1 and β-catenin. A four-protein signature (p70S6K, cyclin B1, pSrc(Y527), and caveolin-1) independent of histology classified specimens as tumor versus normal with a predicted accuracy of 83%, sensitivity of 67%, and specificity of 100%. The signature was validated in the test set, correctly classifying all normal tissues and 14 of 21 tumor tissues. RPPA results were confirmed by immunohistochemistry for caveolin-1 and p70S6K. In tumors from patients with resected NSCLC, expression of proteins in the energy-sensing AMPK pathway (pLKB1, AMPK, p-Acetyl-CoA, pTSC2), adhesion, EGFR, and Rb signaling pathways was inversely associated with NSCLC recurrence. CONCLUSIONS: These data provide evidence for dysregulation of several pathways including those involving energy sensing and adhesion that are potentially associated with NSCLC pathogenesis and disease recurrence.
Authors: David A Eberhard; Bruce E Johnson; Lukas C Amler; Audrey D Goddard; Sherry L Heldens; Roy S Herbst; William L Ince; Pasi A Jänne; Thomas Januario; David H Johnson; Pam Klein; Vincent A Miller; Michael A Ostland; David A Ramies; Dragan Sebisanovic; Jeremy A Stinson; Yu R Zhang; Somasekar Seshagiri; Kenneth J Hillan Journal: J Clin Oncol Date: 2005-07-25 Impact factor: 44.544
Authors: Katherine M Sheehan; Valerie S Calvert; Elaine W Kay; Yiling Lu; David Fishman; Virginia Espina; Joy Aquino; Runa Speer; Robyn Araujo; Gordon B Mills; Lance A Liotta; Emanuel F Petricoin; Julia D Wulfkuhle Journal: Mol Cell Proteomics Date: 2005-01-25 Impact factor: 5.911
Authors: George Deeb; Jianmin Wang; Nithya Ramnath; Harry K Slocum; Sam Wiseman; Amy Beck; Dongfeng Tan Journal: Mod Pathol Date: 2004-04 Impact factor: 7.842
Authors: Kiyoshi Yanagisawa; Yu Shyr; Baogang J Xu; Pierre P Massion; Paul H Larsen; Bill C White; John R Roberts; Mary Edgerton; Adriana Gonzalez; Sorena Nadaf; Jason H Moore; Richard M Caprioli; David P Carbone Journal: Lancet Date: 2003-08-09 Impact factor: 79.321
Authors: Yanyan Lou; Lixia Diao; Edwin Roger Parra Cuentas; Warren L Denning; Limo Chen; You Hong Fan; Lauren A Byers; Jing Wang; Vassiliki A Papadimitrakopoulou; Carmen Behrens; Jaime Canales Rodriguez; Patrick Hwu; Ignacio I Wistuba; John V Heymach; Don L Gibbons Journal: Clin Cancer Res Date: 2016-02-05 Impact factor: 12.531
Authors: Krit Ritthipichai; Cara L Haymaker; Melisa Martinez; Andrew Aschenbrenner; Xiaohui Yi; Minying Zhang; Charuta Kale; Luis M Vence; Jason Roszik; Yared Hailemichael; Willem W Overwijk; Navin Varadarajan; Roza Nurieva; Laszlo G Radvanyi; Patrick Hwu; Chantale Bernatchez Journal: Clin Cancer Res Date: 2017-07-28 Impact factor: 12.531
Authors: Robert J Cardnell; Ying Feng; Lixia Diao; You-Hong Fan; Fatemah Masrorpour; Jing Wang; Yuqiao Shen; Gordon B Mills; John D Minna; John V Heymach; Lauren A Byers Journal: Clin Cancer Res Date: 2013-09-27 Impact factor: 12.531
Authors: Monique B Nilsson; Huiying Sun; Lixia Diao; Pan Tong; Diane Liu; Lerong Li; Youhong Fan; Alissa Poteete; Seung-Oe Lim; Kathryn Howells; Vincent Haddad; Daniel Gomez; Hai Tran; Guillermo Armaiz Pena; Lecia V Sequist; James C Yang; Jing Wang; Edward S Kim; Roy Herbst; J Jack Lee; Waun Ki Hong; Ignacio Wistuba; Mien-Chie Hung; Anil K Sood; John V Heymach Journal: Sci Transl Med Date: 2017-11-08 Impact factor: 17.956